Meyer Handelman Company’s Teva Pharmaceuticals TEVA Stock Holding History

Meyer Handelman Company’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-6,950	Closed	-$231K	–	195
2017 Q2	$231K	Hold	6,950	–	–	0.01%	185
2017 Q1	$223K	Buy	+6,950	New	+$237K	0.01%	184
2016 Q4	–	Sell	-7,450	Closed	-$343K	–	189
2016 Q3	$343K	Hold	7,450	–	–	0.02%	167
2016 Q2	$374K	Hold	7,450	–	–	0.02%	162
2016 Q1	$399K	Hold	7,450	–	–	0.02%	165
2015 Q4	$489K	Hold	7,450	–	–	0.02%	155
2015 Q3	$421K	Hold	7,450	–	–	0.02%	158
2015 Q2	$440K	Buy	7,450 +600	+9%	+$37K	0.02%	160
2015 Q1	$427K	Hold	6,850	–	–	0.02%	162
2014 Q4	$394K	Hold	6,850	–	–	0.02%	165
2014 Q3	$368K	Hold	6,850	–	–	0.02%	164
2014 Q2	$359K	Hold	6,850	–	–	0.02%	163
2014 Q1	$362K	Hold	6,850	–	–	0.02%	161
2013 Q4	$275K	Buy	6,850 +600	+10%	+$23.6K	0.01%	176
2013 Q3	$236K	Hold	6,250	–	–	0.01%	176
2013 Q2	$245K	Buy	+6,250	New	+$243K	0.01%	170

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Meyer Handelman Company's TEVA Position: Q3 2017 in Review

Meyer Handelman Company sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 6,950 shares — an estimated $231K sold.

Meyer Handelman Company first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $489K in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Meyer Handelman Company reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Meyer Handelman Company sold 6,950 Teva Pharmaceuticals shares in Q3 2017, an estimated $231K.
Meyer Handelman Company first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Meyer Handelman Company's Teva Pharmaceuticals position peaked at $489K in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Meyer Handelman Company's 13F filing for Q3 2017, filed 25 Oct 2017.